Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 22 days ago
Share
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
830 patients around the world
Available in
Chile
Merck Sharp & Dohme Corp.
3
Research sites
830
Patients around the world
This study is for people with
Solid tumors
Advanced tumors
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
Sites
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
View site
Manzano 343, Recoleta, Región Metropolitana, Santiago
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
View site
Manzano 343, Recoleta, Región Metropolitana, Santiago
Instituto Oncológico FALP - UIDO
Recruiting
View site
José Manuel Infante 805, Providencia, Región Metropolitana
Instituto Oncológico FALP - UIDO
Recruiting
View site
José Manuel Infante 805, Providencia, Región Metropolitana
Centro de Estudios Clínicos SAGA - CECSAGA
Recruiting
View site
Antonio Varas 517, 7500653 Providencia, Región Metropolitana
Centro de Estudios Clínicos SAGA - CECSAGA
Recruiting
View site
Antonio Varas 517, 7500653 Providencia, Región Metropolitana
See details
Contact us
Contact us
Study
MK-1084-001
Sponsor
Merck Sharp & Dohme Corp.
Study type
Interventional
Conditions
Solid tumors
Requirements
From 18 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT05067283
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent